NurExone Biologic Valuation
Is J90 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of J90 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate J90's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate J90's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for J90?
Key metric: As J90 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is J90's PB Ratio? | |
|---|---|
| PB Ratio | 15.6x |
| Book | US$2.58m |
| Market Cap | US$42.21m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -9.8x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does J90's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 5.1x | ||
SBX SynBiotic | 1.8x | 107.0% | €29.9m |
HIGH Cantourage Group | 1.2x | 112.7% | €56.9m |
B8FK Biofrontera | 0.9x | n/a | €16.7m |
0RX Redx Pharma | 16.6x | -22.3% | €65.0m |
J90 NurExone Biologic | 15.6x | n/a | €59.0m |
Price-To-Book vs Peers: J90 is expensive based on its Price-To-Book Ratio (15.6x) compared to the peer average (5.1x).
Price to Book Ratio vs Industry
How does J90's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 10 Companies | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 10 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: J90 is expensive based on its Price-To-Book Ratio (15.6x) compared to the European Pharmaceuticals industry average (2.2x).
Price to Book Ratio vs Fair Ratio
What is J90's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 15.6x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate J90's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Regeneron Pharmaceuticals
US$80.1b
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
RGO
US$710.80
7D
-7.8%
1Y
-3.7%
Aspen Pharmacare Holdings
R76.1b
Manufactures and supplies specialty and branded pharmaceutical products worldwide.
LDZA
R9.00
7D
-0.6%
1Y
7.1%
Pharming Group
€475.9m
A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.
PHGN
€0.70
7D
-2.0%
1Y
-33.5%